Our summary
Most induction regimens for multiple myeloma (MM) contain bortezomib, usually administered intravenously or subcutaneously twice a week in 21-day or 28-day cycles in clinical trials. However, retrospective single-center studies and secondary analysis from a phase-III trial suggested that once-weekly bortezomib is as effective and causes less peripheral neuropathy than the twice-weekly schedule. Consequently, many doctors have started using once-weekly bortezomib in regular patient care. However, the real-world usage and effectiveness of once-weekly versus twice-weekly bortezomib in a broader population haven’t been well understood.
This study aimed to fill this knowledge gap by examining the contemporary use and effectiveness between different bortezomib schedules.
Why this matters
This research is vital as it explores real-world bortezomib prescribing patterns in patients with MM, reflecting contemporary treatment trends and outcomes. Despite a shift towards once-weekly dosing, a substantial number still receive the twice-weekly regimen. Notably, both schedules demonstrate comparable effectiveness in terms of progression-free and overall survival. Along with previous evidence, these findings advocate for reconsidering bortezomib dosing standards, emphasizing the potential for improved outcomes and experiences for patients across various treatment settings.